Bridging innovation with global opportunity

Founded 2014 | St Andrews, Scotland

Eos invests in, & commercialises, science & technology, from local seed-stage to global scale, with a focus on improving lives.

Deep roots in Scotland, with a global perspective.

Eos is a trusted link between non-specialist investors and knowledge intensive science and technology companies.

The portfolio is split between quality of life and environmental sustainability, and includes disease diagnostics, prevention, and treatment as well as food and water security, addressing pollution, clean energy and sustainable infrastructure.

Motivation for all parties is commensurate financial returns for early-stage patient capital allocation, in businesses that are creating positive impact.

Eos works in long-term partnerships with family offices, individuals, companies and institutional investors.

Eos is committed to building a diverse and inclusive organisation through the investments we make, our investors, and our team.

Amongst the first signatories to the Pathways Pledge our actions include hosting events to improve accessibility of investment, as well as ensuring a diverse selection panel.

Meet some of our Founders & CEO’s

Ishani Malhotra

Carcinotech is a MedTech company manufacturing 3D printed mini tumours developed from patient-specific cancer stem cells, primary cells and established cell lines.
Eos first invested: April, 2022

Giovanna Laudisio

Biodegradable, sustainable and cost competitive cellulose microparticles to replace plastic microbeads
Eos first invested: June, 2022

Richard Hammond

Penrhos Bio offers Remora technology, inspired by nature, that protects against bacteria, fungi, and algae, to provide self-cleaning surfaces.
Eos first invested: September, 2022

Prof. Matthew J Baker

Offers a revolutionary spectroscopic liquid biopsy with artificial intelligence for the early detection of cancer and other diseases.
Eos first invested: February, 2019

David Venables

Laverock Therapeutics is developing a unique gene silencing platform for the creation of programmable advanced therapies.
Eos first invested: June, 2023

Rowan Armstrong

Bioliberty creates soft robotics technology to provide social care services to improve patient outcomes.
Eos first invested: April, 2023

Team

The Eos team is made up of founders, scientists, record breakers, industry leaders, and government advisors.

Eos has a long-term partnership approach with like-minded individuals, family offices & companies.

The funding model works across seed & growth stages, on a managed or discretionary basis.  Investment relationships range from multistage and multiyear through to the original angel syndicate.  Offers S/EIS UK tax relief for relevant investors when available.

News

Eos leads £7.8m Series A into Naturbeads

November 14, 2024

Read more

Laverock makes significant advances in gene silencing platform

November 11, 2024

Read more

Novosound Develops World’s First Ultrasound Blood Pressure Monitor

October 29, 2024

Read more

Get in touch

Angel Syndicate

  • Eos arranges, members make decisions
  • Initial equity investment & follow-ons within existing portfolio
  • Minimum investment of £5k per investment
  • The founding pillar of Eos, accounting for c. 13% of investments per annum
  • Meetings happen virtually on a monthly basis & in-person each quarter

Innovation Fund

  • Eos manages
  • Seed round investments
  • Annual close (Q4), minimum of £25k with a typical range of £100k-£500k
  • 5-8 investments per year
  • Each ‘vintage’ is separate, but most investors invest each year

Venture Partners

  • Eos arranges, members make decisions
  • For growth rounds & Series A+
  • Opportunities presented on ad-hoc basis
  • Minimum of £25k with typical range of £100k-£1M+ in any one deal
  • Opportunities normally grown out of Innovation Fund, but occasionally from wider market

Latest news

Eos leads £7.8m Series A into Naturbeads
14 November 2024
Laverock makes significant advances in gene silencing platform
11 November 2024

This website uses cookies to ensure you get the best experience on our website. By continuing to browse on this website, you accept the use of cookies for the above purposes.